Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5187414
Max Phase: Preclinical
Molecular Formula: C18H19FN4O2
Molecular Weight: 342.37
Associated Items:
ID: ALA5187414
Max Phase: Preclinical
Molecular Formula: C18H19FN4O2
Molecular Weight: 342.37
Associated Items:
Canonical SMILES: Cn1ccc2ncnc(Nc3ccc(F)cc3O[C@@H]3CCCOC3)c21
Standard InChI: InChI=1S/C18H19FN4O2/c1-23-7-6-15-17(23)18(21-11-20-15)22-14-5-4-12(19)9-16(14)25-13-3-2-8-24-10-13/h4-7,9,11,13H,2-3,8,10H2,1H3,(H,20,21,22)/t13-/m1/s1
Standard InChI Key: WSLNKDCNHNOGHL-CYBMUJFWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 342.37 | Molecular Weight (Monoisotopic): 342.1492 | AlogP: 3.41 | #Rotatable Bonds: 4 |
Polar Surface Area: 61.20 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 3.97 | CX LogP: 3.20 | CX LogD: 3.20 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.79 | Np Likeness Score: -0.84 |
1. Xu W, Kannan S, Verma CS, Nacro K.. (2022) Update on the Development of MNK Inhibitors as Therapeutic Agents., 65 (2.0): [PMID:34533957] [10.1021/acs.jmedchem.1c00368] |
Source(1):